Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions.

Fiche M, Scabia V, Aouad P, Battista L, Treboux A, Stravodimou A, Zaman K; RLS, Dormoy V, Ayyanan A, Sflomos G, Brisken C.

J Pathol. 2019 Mar;247(3):287-292. doi: 10.1002/path.5200. Epub 2018 Dec 27.

2.

Oestrogen receptor α AF-1 and AF-2 domains have cell population-specific functions in the mammary epithelium.

Cagnet S, Ataca D, Sflomos G, Aouad P, Schuepbach-Mallepell S, Hugues H, Krust A, Ayyanan A, Scabia V, Brisken C.

Nat Commun. 2018 Nov 9;9(1):4723. doi: 10.1038/s41467-018-07175-0.

3.

The challenges of modeling hormone receptor-positive breast cancer in mice.

Özdemir BC, Sflomos G, Brisken C.

Endocr Relat Cancer. 2018 May;25(5):R319-R330. doi: 10.1530/ERC-18-0063. Epub 2018 Mar 21. Review.

PMID:
29563191
4.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

5.

A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response.

Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, Raffoul W, Delaloye JF, Treboux A, Fiche M, Vilo J, Ayyanan A, Brisken C.

Cancer Cell. 2016 Mar 14;29(3):407-422. doi: 10.1016/j.ccell.2016.02.002. Epub 2016 Mar 3.

6.

An ex vivo model to study hormone action in the human breast.

Sflomos G, Shamsheddin M, Brisken C.

J Vis Exp. 2015 Jan 8;(95):e52436. doi: 10.3791/52436.

7.

A new Achilles Heel in breast cancer?

Sflomos G, Brisken C.

Oncotarget. 2013 Aug;4(8):1126-7. No abstract available.

8.

Progesterone/RANKL is a major regulatory axis in the human breast.

Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, Yalcin-Ozuysal O, Brisken C.

Sci Transl Med. 2013 Apr 24;5(182):182ra55. doi: 10.1126/scitranslmed.3005654.

9.

SARA and RNF11 interact with each other and ESCRT-0 core proteins and regulate degradative EGFR trafficking.

Kostaras E, Sflomos G, Pedersen NM, Stenmark H, Fotsis T, Murphy C.

Oncogene. 2013 Oct 31;32(44):5220-32. doi: 10.1038/onc.2012.554. Epub 2012 Dec 10.

PMID:
23222715
10.

ERBIN is a new SARA-interacting protein: competition between SARA and SMAD2 and SMAD3 for binding to ERBIN.

Sflomos G, Kostaras E, Panopoulou E, Pappas N, Kyrkou A, Politou AS, Fotsis T, Murphy C.

J Cell Sci. 2011 Oct 1;124(Pt 19):3209-22. doi: 10.1242/jcs.062307. Epub 2011 Aug 30.

11.

The histone chaperone SET/TAF-Ibeta interacts functionally with the CREB-binding protein.

Karetsou Z, Martic G, Sflomos G, Papamarcaki T.

Biochem Biophys Res Commun. 2005 Sep 23;335(2):322-7.

PMID:
16061203

Supplemental Content

Loading ...
Support Center